Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;7(4):369–386. doi: 10.1111/j.1527-3458.2001.tb00205.x

Eptastigmine: Ten Years of Pharmacology, Toxicology, Pharmacokinetic, and Clinical Studies

Daniela Braida 1, Mariaelvina Sala 1,✉
PMCID: PMC6741646  PMID: 11830755

ABSTRACT

Eptastigmine (heptyl‐physostigmine tartrate) is a carbamate derivative of physostigmine in which the carbamoylmethyl group in position 5 of the side chain has been substituted with a carbamoylheptyl group. In vitro and ex vivo results suggest that eptastigmine has a long‐lasting reversible brain cholinesterase (i.e., acetylcholinesterase and butyrylcholinesterase) inhibitory effect. When administered in vivo to rodents by various routes, eptastigmine inhibits cerebral acetylcholinesterases (AChE) and increases acetylcholine (Ach) brain levels by 2500–3000%, depending on the dose. This effect leads to an improvement in the cerebral blood flow in the ischemic brain, excitatory and inhibitory effects on the gastrointestinal tract and to a protection from acute soman and diisopropylflu‐orophosphate intoxication.

Eptastigmine, by either acute or chronic administration, has been found to have memory enhancing effects in different species of normal, aged and lesioned animals. It also restored to normal the age‐related increase of EEG power without affecting spontaneous motor activity.

Clinical investigations on more than 1500 patients with Alzheimer's disease demonstrated that eptastigmine significantly improved cognitive performance (as assessed by the cognitive subscale of the Alzheimer's Disease Assessment Scale) as compared with placebo. This improvement was most evident in patients with more severe cognitive impairment at the baseline. The relationship between patient performance and average steady‐state AChE inhibition was described by an inverted U‐shaped dose‐response curve.

Pharmacokinetic studies have revealed that after oral administration eptastigmine is rapidly distributed to the tissues and readily enters the CNS, where it can be expected to inhibit AChE for a prolonged period.

Eptastigmine is generally well tolerated and the majority of adverse events (cholinergic) were mild to moderate in intensity. However, the adverse hematologic (granulocytopenia) effects reported in two studies have resulted in the suspension of further clinical trials.

Keywords: Acetylcholine, Alzheimer's disease, Cholinesterase inhibitors, Cognition‐Eptastigmine

Full Text

The Full Text of this article is available as a PDF (190.6 KB).

References

  • 1. Anderson DJ, Arneric SP. Nicotinic receptor binding of [3H]cytisine, [3H]nicotine and [3H]methylcarbamyl‐choline in rat brain. Eur J Pharmacol 1994;253:261–267. [DOI] [PubMed] [Google Scholar]
  • 2. Auteri A, Mosca A, Lattuada N, Luzzana M, Zecca L, Imbimbo BP. Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects. Eur J Clin Pharmacol 1993;45:373–376. [DOI] [PubMed] [Google Scholar]
  • 3. Becker RE, Moriearty P, Unni L. The second generation of cholinesterase inhibitors: Clinical and pharmacological effects In: Becker RE. and Giacobini E, Eds. Cholinergic basis for Alzheimer's therapy. Boston : Birkhauser, 1991;211–215. [Google Scholar]
  • 4. Bjornsson TD, Troetel WM, Imbimbo BP. Effect of food of the absorption of eptastigmine. Eur J Clin Pharmacol 1998;54:243–247. [DOI] [PubMed] [Google Scholar]
  • 5. Braida D. Eptastigmine: A view point. CNS Drugs 1998;9:76. [Google Scholar]
  • 6. Braida D, Ottonello F, Sala M. Eptastigmine improves eight arm radial maze performance in aged rats. Pharmacol Res 2000;42:299–303. [DOI] [PubMed] [Google Scholar]
  • 7. Braida D, Ottonello F, Sala M. Eptastigmine restores the aged rat's normal cortical spectral power pattern. Pharmacol Res 2000;42:495–500. [DOI] [PubMed] [Google Scholar]
  • 8. Braida D, Paladini E, Griffini P, Lamperti M, Maggi A, Sala M. An inverted U‐shaped curve for heptylphy‐sostigmine on radial maze performance in rats: Comparison with other cholinesterase inhibitors. Eur J Pharmacol 1996;302:13–20. [DOI] [PubMed] [Google Scholar]
  • 9. Braida D, Sala M. Cannabinoid‐induced working memory impairment is reversed by a second cholinesterase inhibitor in rats. Neuroreport 2000;11:2025–2029. [DOI] [PubMed] [Google Scholar]
  • 10. Braida D, Virag W, Ottonello F, Sala M. Excitatory and inhibitory effects of second‐generation cholinesterase inhibitor on rat gastrointestinal transit. Pharmacol Res 2000;41:671–677. [DOI] [PubMed] [Google Scholar]
  • 11. Brufani M, Castellano C, Marta M, Oliverio A, Pavone F, Pomponi M. National Research Council: European patent No. 85101945.5–1985.
  • 12. Brufani M, Castellano C, Marta M, et al. A long‐lasting cholinesterase inhibitor affecting neural and behavioral processes. Pharmacol Biochem Behav 1987;26:625–629. [DOI] [PubMed] [Google Scholar]
  • 13. Brufani M, Marta M, Pomponi M. Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer‐type dementia. Eur J Biochem 1986;157:115–120. [DOI] [PubMed] [Google Scholar]
  • 14. Camacho F, Smith CP, Vargas HN, Winslow JT. Alpha2 adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat. Psychopharmacology 1996;124:347–354. [DOI] [PubMed] [Google Scholar]
  • 15. Canal N, Franceschi M. and the Italian eptastigmine Investigators. A double‐blind, placebo‐controlled, clinical trial in Alzheimer disease patients In: Giacobini E, Becker R. eds. Alzheimer disease therapeutic strategies. Boston : Birkhaeuser, 1994;108–112. [Google Scholar]
  • 16. Canal N, Imbimbo BP. Eptastigmine Study Group. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Clin Pharmacol Ther 1996;60:218–228. [DOI] [PubMed] [Google Scholar]
  • 17. Cattaneo L, Bondiolotti GP, Muller EE, Cocchi D. Effect of acute and short‐term administration of cholinomimetic drugs on corticosterone secretion in the rat. Eur J Pharmacol 1993;2–3:245–248. [DOI] [PubMed] [Google Scholar]
  • 18. Cazzola E, Lattuada N, Zecca L, et al. A rapid potentiometric determination of cholinesterase in plasma and red cells: Application to eptastigmine monitoring. Chem Biol Interactions 1993;87:265–268. [DOI] [PubMed] [Google Scholar]
  • 19. Cella SG, Imbimbo BP, Pieretti F, Muller EE. Eptastigmine augments basal and GHRH‐stimulated growth hormone release in young and old dogs. Life Sci 1993;5:389–395. [DOI] [PubMed] [Google Scholar]
  • 20. Cuadra G, Giacobini E. Coadministration of cholinesterase inhibitors and idazoxan: Effects of neurotransmitters in rat cortex in vivo. J Pharmacol Exp Ther 1995;273:230–240. [PubMed] [Google Scholar]
  • 21. Cuadra G, Summers K, Giacobini E. Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo. J Pharmacol Exp Ther 1994;270:277–284. [PubMed] [Google Scholar]
  • 22. Cutler NR, Sramek JJ. Target population in phase‐I clinical‐trials of cholinergic compounds in Alzheimer's disease. The role of the bridging study. Alzheimer Dis Assoc Disord 1995;9:139–135. [PubMed] [Google Scholar]
  • 23. Dawson GR, Bentley G, Draper F, Rycroft W, Iversen SD, Pagella PG. The behavioral effects of heptyl physostigmine, a new cholinesterase inhibitor, in tests of long‐term and working memory in rodents. Pharmacol Biochem Behav 1991;39:865–871. [DOI] [PubMed] [Google Scholar]
  • 24. Dawson GR, Iversen SD. The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. Behav Brain Res 1993;57:143–153. [DOI] [PubMed] [Google Scholar]
  • 25. De Sarno P, Pomponi M, Giacobini E, Tang XC, Williams E. The effect of heptylphysostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat. Neurochem Res 1989;14:971–977. [DOI] [PubMed] [Google Scholar]
  • 26. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowski CH, Dolan‐Ureno JA. Controlled trial of tacrine in Alzheimer's disease. J Am Med Ass 1992;268:2523–2529. [PubMed] [Google Scholar]
  • 27. Garrone B, Luparini MR, Tolu L, Magnani M, Landolfi C, Milanese C. Effect of the subchronic treatment with the acetylcholinesterase inhibitor heptastigmine on central cholinergic transmission and memory impairment in aged rats. Neurosci Lett 1998;245:53–57. [DOI] [PubMed] [Google Scholar]
  • 28. Giacobini E. From molecular structure to Alzheimer therapy. Jpn J Pharmacol 1997;74:225–241. [DOI] [PubMed] [Google Scholar]
  • 29. Giacobini E. Cholinesterase inhibitors for Alzheimer's disease therapy: From tacrine to future applications. Neurochem Int 1998;32:413–419. [DOI] [PubMed] [Google Scholar]
  • 30. Giacobini E. Cholinergic foundation of Alzheimer's disease therapy. J Physiol (Paris) 1998;92:283–287. [DOI] [PubMed] [Google Scholar]
  • 31. Giubilei F., Imbimbo BP, Tisei P. et al. Power spectral analysis of heart rate variability in Alzheimer's disease patients treated with cholinesterase inhibitor. Neurology 1996;46(Suppl S): 3074. [Google Scholar]
  • 32. Iijima S, Greig NH, Garofalo P, et al. The long‐acting cholinesterase inhibitor heptylphysostigmine attenuates the scopolamine‐induced learning impairment of rats in a 14‐unit T‐maze. Neurosci Lett 1992;144:79–83. [DOI] [PubMed] [Google Scholar]
  • 33. Imbimbo BP. Eptastigmine: A cholinergic approach to the treatment of Alzheimer's disease In: Becker R, Giacobini E, Eds. Alzheimer's disease: From molecular biology to therapy. Boston : Birkhauser, 1996;223–230. [Google Scholar]
  • 34. Imbimbo BP, Licini M, Schettino M. et al. Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers. J Clin Pharmacol 1995;35:285–290. [DOI] [PubMed] [Google Scholar]
  • 35. Imbimbo BP, Lucca U, Lucchelli F, Alberoni M, Thal LJ. A 25‐week placebo‐controlled study of eptastigmine in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 1998;12:312–322. [DOI] [PubMed] [Google Scholar]
  • 36. Imbimbo BP, Martelli P, Troetel WM, et al. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. Neurology 1999;52:700–708. [DOI] [PubMed] [Google Scholar]
  • 37. Imbimbo BP, Troetel WM, Martelli P., Lucchelli F. and the Eptastigmine Study Group. A 6‐month, double‐blind, placebo‐controlled trial of eptastigmine in Alzheimer's disease. Dement Geriatr Cogn Disord 2000;11:17–24. [DOI] [PubMed] [Google Scholar]
  • 38. Imbimbo BP, Verdelli G., Martelli P., Marchesini D. Two‐year treatment of Alzheimer's disease with eptastigmine. Dement Geriatr Cogn Disord 1999;10:139–147. [DOI] [PubMed] [Google Scholar]
  • 39. Iversen LL. Approaches to cholinergic therapy in Alzheimer's disease. Prog Brain Res 1993;98:423–426. [DOI] [PubMed] [Google Scholar]
  • 40. Lines CR, Ambrose JH, Heald A, Traub M. A double‐blind, placebo‐controlled study of the effects of eptastigmine on scopolamine‐induced cognitive deficits in healthy male‐subjects. Hum Psychopharm Clin 1993;8:271–278. [Google Scholar]
  • 41. Linville DG, Giacobini E, Arneric SP. Heptylphysostigmine enhances basal forebrain control of cortical cerebral blood flow. J Neurosci Res 1992;31:573–577. [DOI] [PubMed] [Google Scholar]
  • 42. Liu WF. Effects of cholinesterase inhibitors on a two‐component chained schedule performance. Neurotoxicol Teratol 2000;22:389–396. [DOI] [PubMed] [Google Scholar]
  • 43. Mant T, Troetel WM, Imbimbo BP. Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers. J Clin Pharmacol 1998;38:610–617. [DOI] [PubMed] [Google Scholar]
  • 44. Mayeux R, Sano M. Drug therapy: Treatment of Alzheimer's disease. New Engl J Med 1999;341:1670–1679. [DOI] [PubMed] [Google Scholar]
  • 45. McClellan K, and Benfield P. Eptastigmine. CNS Drugs 1998;9:69–75. [Google Scholar]
  • 46. Mori F, Lai C‐C, Fusi F, Giacobini E. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroreport 1995;6:633–636. [DOI] [PubMed] [Google Scholar]
  • 47. Moriearty PL. Transdermal delivery of cholinesterase‐inhibitors. Rationale and therapeutic potential. CNS Drugs 1995;4:323–334. [Google Scholar]
  • 48. Moriearty PL, Becker RE. Inhibition of human brain and RBC acetylcholinesterase (AChE) by heptylphysostigmine (HPTL). Meth Find Exp Clin Pharmacol 1992;14:615–621. [PubMed] [Google Scholar]
  • 49. Mosca A, Onelli E, Rosti E, Paleari M, Luzzana M, and Imbimbo BP. A patient‐side technique for real‐time measurement of acetylcholinesterase activity during monitoring of eptastigmine treatment. Ther Drug Monit 1995;17:230–238. [DOI] [PubMed] [Google Scholar]
  • 50. Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology. Drug Safety 1998;19:465–480. [DOI] [PubMed] [Google Scholar]
  • 51. Ogane N, Giacobini E, Messamore E. Preferential inhibition of acetylcholinesterase molecular forms in rat brain. Neurochem Res 1992;17:489–495. [DOI] [PubMed] [Google Scholar]
  • 52. Ogane N, Giacobini E, Struble R. Differential inhibition of acetylcholinesterase molecular forms in normal and Alzheimer disease brain. Brain Res 1992;589:307–312. [DOI] [PubMed] [Google Scholar]
  • 53. Perini M, Montanini R, Casucci R. Effects of eptastigmine, a new cholinesterase inhibitor, on regional cerebral blood flow in Alzheimer patients. J Neurol 1995(Suppl 2): 242. [Google Scholar]
  • 54. Rupniak NMJ. Profile of cholinomimetic drugs in primates‐status of screens for potential Alzheimer therapies. Drug Dev Res 1992;27:77–88. [Google Scholar]
  • 55. Rupniak NMJ, Tye SJ, Brazell C, Heald A, Iversen SD, Pagella PG. Reversal of cognitive impairment by heptyl‐physostigmine, a long‐lasting cholinesterase inhibitor, in primates. J Neurol Sci 1992;107:246–249. [DOI] [PubMed] [Google Scholar]
  • 56. Scremin OU, Heuser D, Hudgell R, Romero E, Imbimbo BP. Prolonged effects of cholinesterase inhibition with eptastigmine on the cerebral blood flow‐metabolism ratio of normal rats. J Cerebr Blood Flow Metab 1993;13:702–711. [DOI] [PubMed] [Google Scholar]
  • 57. Scremin OU, Li MG, Scremin AME, Jenden DJ. Cholinesterase inhibition improves blood flow in the ischemic cerebral cortex. Brain Res Bull 1997;42:59–70. [DOI] [PubMed] [Google Scholar]
  • 58. Segre G, Cerretani D, Baldi A, Urso R. Pharmacokinetics of heptastigmine in rats. Pharmacol Res 1992;25:139–146. [DOI] [PubMed] [Google Scholar]
  • 59. Sramek JJ, Block GA, Reines SA et al. A multiple‐dose safety trial of eptastigmine in Alzheimer's desease, with pharmacodynamic observations of red blood cell cholinesterase. Life Sci 1994;56:319–326. [DOI] [PubMed] [Google Scholar]
  • 60. Tabano MT, Luzi M, Palazzesi S, Pomponi M, Loizzo A. Effects of cholinergic drugs on neocortical EEG and flash visual evoked potentials in the mouse. Neuropsychobiology 1999;40:47–56. [DOI] [PubMed] [Google Scholar]
  • 61. Tuovinen K, Kalistekorhonen E, Raushel FM, Hanninen O. Eptastigmine‐phosphotriesterase combination in DFP intoxication. Toxicol Appl Pharm 1996;140:364–369. [DOI] [PubMed] [Google Scholar]
  • 62. Tuovinen K, Hanninen O. Protection of mice against soman by pretreatment with eptastigmine and physostigmine. Toxicology 1999;139:233–241. [DOI] [PubMed] [Google Scholar]
  • 63. Tuovinen K, Kalistekorhonen E, Raushel FM, Hanninen O. Phosphotriesterase pralidoxime‐2‐chloride (2‐PAM) and eptastigmine treatments and their combinations in DFP intoxication. Toxicol Appl Pharm 1996;141:555–560. [DOI] [PubMed] [Google Scholar]
  • 64. Tuovinen K, Kalistekorhonen E, Raushel FM, Hanninen O. Success of pyridoxstigmine, physostigmine, eptastigmine and phosphotriesterase treatments in acute sarin intoxication. Toxicology 1999;134:169–178. [DOI] [PubMed] [Google Scholar]
  • 65. Unni LK, Becker RE. Determination of heptylphysostigmine by high‐performance liquid chromatography with electrochemical detection. J Chromatogr 1992;573:275–281. [DOI] [PubMed] [Google Scholar]
  • 66. Unni LK, Hutt V, Imbimbo BP et al., Kinetics of cholinesterase inhibition by eptastigmine in man. Eur J Clin Pharmacol 1991;41:83–84. [DOI] [PubMed] [Google Scholar]
  • 67. Waite JJ, Thal LJ. The behavioral effects of heptylphysostigmine on rats lesioned in the nucleus accumbens. Neurosci Res 1995;21:251–259. [DOI] [PubMed] [Google Scholar]
  • 68. Winslow JT, Camacho F. Cholinergic modulation of a decrement in social investigation following repeated contacts between mice. Psychopharmacology 1995;121:164–172. [DOI] [PubMed] [Google Scholar]
  • 69. Zecca L, Radice D, Mosca A, Pagella PG. Determination of heptylphysostigmine in plasma by high‐performance liquid chromatography with electrochemical detection. J Chromatogr Biomed Appl 1993;615:169–173. [DOI] [PubMed] [Google Scholar]
  • 70. Zhu XD, Cuadra G, Brufani M, et al. Effects of MF268, a new cholinesterase inhibitor, on acetylcholine and biogenic amines in rat cortex. J Neurosci Res 1996;43:120–126. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES